Neurogastrx
develops and commercializes transformative therapies for the treatment of gastrointestinal disorders... Read moreNeurogastrx
develops and commercializes transformative therapies for the treatment of gastrointestinal disorders... Read more
News
Oct 07, 2025
GlobalNewswire
Press Release: Neurogastrx : Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek
Oct 16, 2024
Endpoints News
Neurogastrx: GLP-1 side effect treatment data released by Neurogastrx
Oct 16, 2024
StreetInsider
Press Release: Neurogastrx : Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication
Aug 26, 2021
Venture Capital Journal
Neurogastrx: Neurogastrx rakes in $60m Series B
Aug 26, 2021
Endpoints News
Neurogastrx: After pandemic delay and a South Korean deal, Boston-area biotech raises Series B with sights on IPO
Aug 26, 2021
BioCentury
Neurogastrx: Neurogastrx: $60M crossover round to advance de-risked GI assets
Jun 09, 2021
The Korea Herald
Neurogastrx: Daewoong Pharmaceutical signs $430m licensing deal for Fexuprazan
Jun 08, 2021
Korea Biomedical Review
Neurogastrx: Daewoong licenses out gastroesophageal reflux drug to US firm
Jan 04, 2018
BioSpace
Neurogastrx: Neurogastrx Bags $45M, a New CEO and a HQ Move to the Greater Boston Area
Jan 04, 2018
VC News Daily
Neurogastrx: Neurogastrx Raises $45M
